Factory 99% Purity Dapagliflozin Powder Antidiabetic Drugs CAS 461432-26-8
Product Description
Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor. On January 8, 2014, the US Food and Drug Administration (FDA) have approved it for being used in the treatment of type II diabetes. Meanwhile, FDA requires the producers to conduct post-marketing research on drug-related risks.
| Product name | Dapagliflozin |
| CAS | 461432-26-8 |
| Appearance | white powder |
| Assay | 99% |
| Storage | Cool and Protect from light |
Function and Application
Dapagliflozin is a drug used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.Although dapagliflozin's method of action would operate on both types of diabetes and other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with type 1 diabetes.
